Current treatment for combatting Chagas disease, a life-threatening illness caused by the kinetoplastid protozoan parasite Trypanosoma cruzi is inadequate, and thus the discovery of new antipar
Half maximal effective concentration (mg mL-1; EC50) obtained for protein fractions of Spigelia anthelmia against Haemonchus contortus eggs and larvae.
Technological advancements in the North America Antiparasitic Drugs industry are shaping the future market landscape. The report evaluates innovation-driven growth and how emerging technologies are tr
